Skip to main content

Jason Flowerday

3D Signatures has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the company's board of directors. Flowerday has more than a decade of business development and marketing experience in the life sciences, including leadership experience at Bayer and Johnson and Johnson. He has also held executive leadership and entrepreneurial roles with Knight Therapeutics and Pro Bono Bio. Additionally, Flowerday was co-founder and co-owner of both Orphan Canada and RxMedia Healthcare Communications, and he is an independent director of Aequus Pharmaceuticals. 

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.